Contact
searchSearch
HMP Global
Login

Colorectal Cancer

Colorectal Cancer
Specialty Channel
News
Adagrasib Plus Cetuximab Does Not Improve Progression-Free or Overall Survival Over Chemotherapy in KRAS G12C–Mutated Metastatic Colorectal Cancer
07/07/2026
Stephanie Holland
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did...
07/07/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer
05/27/2026
Emily Estrada
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a...
05/27/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Glecirasib Plus Cetuximab Shows Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2...
05/07/2026
Oncology
News
Longitudinal ctDNA Analysis Identifies Patients With Poorer Outcomes in Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
News
Dose-Reduced Chemotherapy Expands Treatment Options for Frail Patients with Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Botensilimab Plus Balstilimab Associated With Improved Survival in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic...
03/18/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Improves Overall Survival in Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3...
02/06/2026
Oncology
News
Tucatinib Plus Trastuzumab Demonstrates Durable Clinical Benefit in HER2-Positive Metastatic Colorectal Cancer
01/27/2026
Emily Estrada
Updated results from the phase 2 MOUNTAINEER trial demonstrated sustained clinical benefit and a manageable safety profile with tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic...
Updated results from the phase 2 MOUNTAINEER trial demonstrated sustained clinical benefit and a manageable safety profile with tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic...
Updated results from the phase 2...
01/27/2026
Oncology

News

News
Adagrasib Plus Cetuximab Does Not Improve Progression-Free or Overall Survival Over Chemotherapy in KRAS G12C–Mutated Metastatic Colorectal Cancer
07/07/2026
Stephanie Holland
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did...
07/07/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer
05/27/2026
Emily Estrada
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a...
05/27/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Glecirasib Plus Cetuximab Shows Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2...
05/07/2026
Oncology
News
Longitudinal ctDNA Analysis Identifies Patients With Poorer Outcomes in Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
News
Dose-Reduced Chemotherapy Expands Treatment Options for Frail Patients with Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY trial demonstrated that dose-reduced chemotherapy regimens show clinical activity with a manageable safety profile in elderly and frail elderly patients with metastatic colorectal cancer.
Results from the phase 2 ELDERLY...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Botensilimab Plus Balstilimab Associated With Improved Survival in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic...
03/18/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Improves Overall Survival in Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3...
02/06/2026
Oncology

Interactive Features

Quiz
Avelumab Following Long-Course Chemoradiotherapy for Patients With Locally Advanced, Resectable Colorectal Cancer
09/30/2025
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial researchers assessed avelumab after long-course chemoradiotherapy among patients with locally advanced, resectable colorectal cancer (CRC). Which of the following statements best summarizes the significance of...
In the phase 2 Ave-Rec trial...
09/30/2025
Oncology
Quiz
Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer
07/29/2025
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the phase 3 ATOMIC trial demonstrated a statistically and clinically significant improvement in survival outcomes with the addition of atezolizumab to standard mFOLFOX6 chemotherapy and a manageable safety profile...
True or False: Results from the...
07/29/2025
Oncology
Quiz
Quiz: Incidence of Anal Cancer
05/18/2023
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has the incidence of anal cancer has increased per year?
By approximately how much has...
05/18/2023
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?
09/03/2021
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.
True or false: Data from the...
09/03/2021
Oncology
Quiz
Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?
08/09/2021
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to enhance tumor immunologic response in patients with LARC?
Which therapy was found to...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Does Coffee Consumption Yield Benefit in CRC?
04/05/2021
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.
True or False: Several compounds...
04/05/2021
Oncology
Test Your Knowledge
Quiz: What Are the 3 Current Modalities for Rectal Cancer?
03/24/2021
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3 current modalities for rectal cancer?
Which of the following are the 3...
03/24/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology

Recent News

News
Adagrasib Plus Cetuximab Does Not Improve Progression-Free or Overall Survival Over Chemotherapy in KRAS G12C–Mutated Metastatic Colorectal Cancer
07/07/2026
Stephanie Holland
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did not demonstrate significant improvements in progression-free or overall survival with adagrasib plus cetuximab versus standard second-line chemotherapy in patients with KRAS G12C-mutated metastatic colorectal...
The phase 3 KRYSTAL-10 trial did...
07/07/2026
Oncology
News
BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
05/31/2026
Stephanie Holland
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...
First-line encorafenib,...
05/31/2026
Oncology
News
Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer
05/27/2026
Emily Estrada
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a...
05/27/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Glecirasib Plus Cetuximab Shows Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2 JAB-21822-1002 and JAB-21822-1007 trials demonstrated that glecirasib, a covalent KRAS G12C inhibitor, showed encouraging clinical activity both as monotherapy and in combination with cetuximab in patients with...
Results from the phase 1/2...
05/07/2026
Oncology
News
Longitudinal ctDNA Analysis Identifies Patients With Poorer Outcomes in Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Botensilimab Plus Balstilimab Associated With Improved Survival in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic comparative analysis suggested that botensilimab plus balstilimab may improve overall survival compared with currently available later-line therapies for patients with refractory microsatellite-stable metastatic...
Results from a systematic...
03/18/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Improves Overall Survival in Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3 STELLAR-303 trial demonstrated that zanzalintinib plus atezolizumab significantly improved overall survival compared with regorafenib in patients with previously treated metastatic colorectal cancer without...
Results from the phase 3...
02/06/2026
Oncology
News
Tucatinib Plus Trastuzumab Demonstrates Durable Clinical Benefit in HER2-Positive Metastatic Colorectal Cancer
01/27/2026
Emily Estrada
Updated results from the phase 2 MOUNTAINEER trial demonstrated sustained clinical benefit and a manageable safety profile with tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic...
Updated results from the phase 2 MOUNTAINEER trial demonstrated sustained clinical benefit and a manageable safety profile with tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic...
Updated results from the phase 2...
01/27/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use